The United States National Institutes of Health led the study. It compared treatment with remdesivir to usual care in 1,063 hospitalized coronavirus patients around the world.
美国国立卫生研究院领导了这项研究。它对全球1063名冠状病毒住院患者中采用瑞德西韦治疗与常规治疗的效果进行了比较。
Anthony Fauci is the NIH's leading infectious disease expert and a member of President Donald Trump's COVID-19 task force.
安东尼·福奇是美国国立卫生研究院的顶尖传染病专家，也是川普总统新冠肺炎工作小组的成员。
Dr. Fauci said the remdesivir reduced recovery time. He said patients who received remdesivir recovered on average four days earlier than those who got usual care.
福奇博士表示，瑞德西韦缩短了患者的康复时间。他说，接受瑞德西韦治疗的患者比接受常规治疗的患者平均能提前4天康复。
"What it has proven is that a drug can block this virus," Fauci said. "This will be the standard of care."
福奇表示：“已经证实这种药物可以阻断新冠病毒，这将成为救治的标准。”
He also said there were fewer deaths among those who took remdesivir. The full results of the study will be published in a medical journal soon, Fauci added.
他还表示，服用瑞德西韦的患者的死亡率也有所降低。福奇还说，这项研究的完整结果很快会在医学杂志上发表。
Nearly 225,000 people have died of COVID-19 and over 3 million have been infected with the coronavirus.
目前已经有近22.5万人死于新冠肺炎，还有超过3百万人感染了这种冠状病毒。
The U.S. Food and Drug Administration said Wednesday that it has been talking with remdesivir maker, Gilead Sciences. The agency wants the company to make the drug "available to patients as quickly as possible..."
美国食品与药品监管局周三表示，它一直在跟瑞德西韦的生产商吉利德科学公司进行讨论。该机构希望该公司尽快将这种药物提供给患者。
However, the drug has not been approved for any use anywhere in the world. Other possible treatments continue to be studied.
然而该药物尚未在全球任何地方被批准用于任何用途。其它可能的治疗方案仍在继续研究中。
Earlier, animal studies showed remdesivir was effective against SARS and MERS, two diseases also caused by coronaviruses. It helped prevent infection and some symptoms when given early enough in the disease process.
此前的动物研究表明瑞德西韦对非典和中东呼吸综合征有效，这两种疾病也是由冠状病毒引起的。当这种药物在疾病过程中应用得足够早时，它有助于预防感染和某些症状。
Remdesivir is administered directly to the bloodstream through IV, a continuous fluid flow device.
瑞德西韦通过静脉注射直接给药至血液中。
"We are excited and optimistic," said Dr. Mark Denison of Vanderbilt University in Nashville, Tennessee. His laboratory tested remdesivir against other coronaviruses in 2013. It was not involved in the NIH study.
田纳西州纳什维尔市范德比尔特大学的马克·丹尼森博士表示：“我们感到兴奋和乐观。”他所在的实验室在2013年使用瑞德西韦对其它冠状病毒进行了试验。该实验室并未参与美国国立卫生研究院的这项研究。
"It's active against every coronavirus that we've ever tested," Denison said. "It was very hard for the virus to develop resistance to remdesivir. That means the drug would likely be effective over longer-term use," he said.
丹尼森表示：“它对我们测试过的每种冠状病毒都有效果。这种病毒很难对瑞德西韦产生耐药性。这意味着该药物可能可以长期使用。”
A less promising result came from an incomplete study of remdesivir on severely sick patients in China. That research found the drug did not speed recovery. However, that examination was halted early, after only about half the expected patients were registered for the study. The incomplete results were reported Wednesday in the British medical journal, Lancet.
中国对重症患者采用瑞德西韦治疗的一项不完全研究表明结果并不乐观。这项研究发现该药物不能加速康复过程。然而，登记参与这项研究的患者人数只有预期的一半左右，导致该研究被提前终止。英国医学杂志《柳叶刀》周三报道了这项不完整的研究结果。
In France, a group of hospitals reported success with use of another drug, Acetemra, against COVID-19. In a study of 129 coronavirus patients, 65 were treated with the drug while the other patients received usual care. The doctors did not release details, but said they were preparing to publish results. Acetemra is used to treat rheumatoid arthritis and other diseases.
在法国，一批医院报告称成功使用另一种Acetemra药物对抗新冠肺炎。在一项涉及129名新冠病毒患者的研究中，有65人接受了该药物的治疗，其它患者则接受了常规治疗。医生并未透露细节，但是表示他们正在准备发表研究结果。Acetemra被用于治疗类风湿关节炎等疾病。
Health officials believe any vaccine for COVID-19 is at least a year away.
卫生官员认为，任何新冠肺炎疫苗的面世至少还需要1年时间。